Sun Pharmaceuticals bags Australia approval for Winlevi
IMT News Desk
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and olderSun Pharmaceutical Industries announced that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval for Winlevi (clascoterone cream 1 per cent). Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.As stated by Hellen de Kloet, Business Head – Western Europe, Australia and New Zealand, Sun Pharma, “Winlevi is an exciting addition to our expanding dermatology portfolio of innovative medicines in Australia. Winlevi’s novel mechanism of action will be a welcome addition to the physician’s toolkit while treating acne.”Diana Harbort, President of the Dermatology Division, Cosmo, said, “We are pleased that Winlevi will soon be available to patients in Australia. This is another achievement in the mission of Cosmo and Sun Pharma to improve the lives of patients affected by skin conditions.”Winlevi will be available in Australia this June.
